ClinConnect ClinConnect Logo
Search / Trial NCT06161038

Precision Medicine for Nociception, Sngception and Proprioception.

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Dec 5, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Sng / Pain Precision Medicine Next Generation Sequencing Proprioception Prolotherapy

ClinConnect Summary

This clinical trial is studying how different treatments can help manage pain and discomfort related to myofascial pain syndrome and idiopathic scoliosis. The researchers are particularly interested in understanding how a person's unique genetic makeup can influence their response to treatments like low-level laser therapy, ultrasound, and prolotherapy. By analyzing blood and urine samples, they hope to find specific markers that can guide personalized treatment plans for better pain relief.

To participate, individuals should be between 20 to 100 years old and diagnosed with myofascial pain syndrome, or between 13 to 65 years old with idiopathic scoliosis confirmed by an X-ray. Participants will receive treatment and their pain levels will be monitored. It's important to note that those with active infections, certain medical conditions, or specific types of scoliosis will not be eligible for this study. This trial aims to improve how pain is treated by tailoring approaches to each person's individual needs based on their genetic information.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1.Cohort A:
  • (1) Age between 20-100 years old. (2) VAS\>=30 or VAS\>=30 at 4 kg pressure (3) Diagnosed as myofascial pain syndrome patients and willing to receive treatment (including LLLT, therapeutic ultrasound, and local dextrose injection therapy) 2. Cohort B:
  • 1. Age between 13-65 years old.
  • 2. Diagnosed as idiopathic scoliosis The diagnosis of scoliosis was confirmed by antero-posterior plain Xray with Cobbs angle larger than 10 degrees.
  • Exclusion Criteria:
  • 1.Cohort A: Those having active infection, malignancy, and hematological diseases were excluded. The patients had received local injection at upper trapezius within 6 months are also excluded.
  • 2.Cohort B:
  • 1. Those having active infection, malignancy, and hematological diseases were excluded.
  • 2. Those having specific etiologies of scoliosis, including congenital scoliosis due to malformation or faulty segmentation of the vertebrae and neuromuscular scoliosis due to muscular imbalance, syndromic scoliosis or degenerative scoliosis.
  • 3. Pregnancy.

About National Taiwan University Hospital

National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.

Locations

Taipei, , Taiwan

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported